SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
Genzyme: Robust Growth Prospects at Clearance Sale Prices
GENZ
|
|
|
+7.95%
in
94 days
In late July, Genzyme (NASDAQ:GENZ) reported 2Q09 results, including revenue of $1.23 billion (up 5% from $1.17 billion during 2Q08 and up 11% excluding unfavorable currency exchange rates). The Company's Non-GAAP net income (which excludes stock compensation and certain business acquisition items) rose to $232.5 million or $0.85 per diluted share versus $107 million or $0.38 per diluted share in the year-ago period. During 2Q09, Genzyme generated about $281 million in cash (primarily derived from operations) and used about $157 million (primarily for investments in manufacturing facilities...
|
FDA Calendar Updates: Genzyme FDA Woes Benefit Protalix, Shire
GENZ
|
|
|
-6.79%
in
7 days
(closed on 08/07/09)
Below is a summary of updates to the BioMedReports.com FDA Calendar , which includes a database of 293 entries as of 7/31/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage clinical trial results. ...
|
FDA, Clinical Trial Updates: GENZ, HGSI, LLY, NGSX
GENZ
|
|
|
-11.86%
in
71 days
(closed on 07/31/09)
<> Below is a summary of updates to the <font> BioMedReports.com </font> database of over 200 entries included in the <font> FDA and Clinical Trial Calendars </font> . The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA fo...
|
FDA, Clinical Trial Calendar Updates: Genzyme, Isis, Osiris, Roche, Watson
GENZ
|
|
|
+12.12%
in
29 days
(closed on 05/21/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete r...
|
Highly Defensive Index: Opportunities in Healthcare
GENZ
|
|
|
-6.57%
in
9 days
(closed on 04/22/09)
The ETF Innovators Highly Defensive Index contains 32 market cap leading companies from the defensive industry groups (A-K) specified below in addition to one position reserved for the SPDR Gold Trust (GLD) as a hedge against long-term inflation and global currency devaluation. Since I last wrote about the index two months ago, Genentech has been acquired by Roche (RHHBY.PK) and the number of securities has been reduced from 40 to 33. Table with Highly Defensive Index stats and benchmark funds: <> http://biomedreports.com/articles/most-popular/805-highly-def... ...
|
From the Blogosphere
Genzyme Corp. (GENZ) – Bear of the Day
|
|
|
Genzyme (GENZ) reported third quarter earnings of 31 cents per share, in-line with the Zacks Consensus Estimate but well below the year-ago earnings of 53 cents per share. Moreover, revenues declined 9% to $1.06 billion.
The company has been under significant pressure following the shutdown of its Allston manufacturing facility in June 2009. The shutdown is a major setback as three drugs -- including key product Cerezyme -- were being manufactured at the facility. Although Genzyme has resumed production, new lots will not be available until later this year.
<>The shutdown has affected the com...
|
Zacks Bull and Bear of the Day Highlights: McDonald’s, Genzyme, Berkshire Hathaway, Burlington Northern Santa Fe Corp and Berkshire Hathaway – Press Releases
|
|
|
For Immediate Release Chicago, IL – November 4, 2009 – Zacks Equity Research highlights McDonald (MCD) as the Bull of the Day and Genzyme (GENZ) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Berkshire Hathaway (BRK.A), Burlington Northern Santa Fe Corp (BNI) and Berkshire Hathaway (BRK.B). Full analysis of all these stocks is available at http://at.zacks.com/?id=5506 Here is a synopsis of all five stocks: Bull of the Day: <>McDonald’s (MCD) global same-store sales continue to grow (up 3.8% in the third quarter of 2009) while maintaining healthy margins and out-...
|
Nasdaq Market Wrap 1 November
The 60-minute trend is down according to the force index indicator. %b has printed a slightly positive divergence. Finally prices have moved quickly to the downside. The Nasdaq is underperforming the Dow and the S&P. In fact, the breakout of the rising trendline has already occurred. On Thursday prices retested the trendline and Friday accelerated to the downsode quite impressively. Support at 1650. Then 1590. Prices are now testing the lower trendline of a channel that prices are forming. I would expect overall a negative week. Many stocks have printed new 20-day low. I remain negative on...
|
Nasdaq Market Wrap 1 November
|
|
|
The 60-minute trend is down according to the force index indicator. %b has printed a slightly positive divergence. Finally prices have moved quickly to the downside. The Nasdaq is underperforming the Dow and the S&P. In fact, the breakout of the rising trendline has already occurred. On Thursday prices retested the trendline and Friday accelerated to the downsode quite impressively. Support at 1650. Then 1590. Prices are now testing the lower trendline of a channel that prices are forming. I would expect overall a negative week. Many stocks have printed new 20-day low. I remain negative on...
|
Nasdaq Market Wrap 25 Oct
|
|
|
The 60-minute trend is down according to the force index indicator. %b has printed a slightly negative divergence. The Nasdaq has managed to print new highs, but actually momentum is very low. Support at 1740. Prices are moving within within a slightly positevely inclined channel. Prices are now testing the lower trendline. I would expect a negative week. Many stocks are still trading above their 20-day moving averages, but the picture is more mixed than last week. Actually only MSFT and AMZN printed a 20-day high on Friday. AMGN, BRCM, CMCSA, DISH, GILD, JAVA, NVDA, QCOM printed a new ...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on GENZ |
Visit streetinsider.com
More Resources
|
About Genzyme Corp.
- Answers.com
